Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications (CAPSTONE 2)

Shionogi

Status and phase

Completed

Phase 3

Conditions

Influenza

Treatments

Drug: Placebo to Baloxavir Marboxil

Drug: Oseltamivir

Drug: Placebo to Oseltamivir

Drug: Baloxavir Marboxil

Study type

Interventional

Funder types

Industry

Identifiers

NCT02949011

1602T0832

2016-002688-32 (EudraCT Number)

Details and patient eligibility

About

The primary objective of this study is to evaluate the efficacy of a single, oral dose of baloxavir marboxil compared with placebo by measuring the time to improvement of influenza symptoms in patients with influenza presenting within 48 hours of symptom onset.

Enrollment

2,184 patients

Sex

All

Ages

12+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Patients or their legal guardians who provide written informed consent to participate in the study on a voluntary basis. For adolescent patients, informed consent/assent of voluntary participation should be obtained in accordance with local requirements.
Male or female patients ≥ 12 years at the time of signing the informed consent/assent form.
Patients with a diagnosis of influenza confirmed by all of the following:
1. Fever ≥ 38ºC (axillary) during the predose examinations or within the 4 hours prior if antipyretics were taken
2. A positive rapid influenza diagnostic test (RIDT) result OR A patient with a negative RIDT may be enrolled if the patient reports contact with a known case of influenza within the prior 7 days and all other inclusion criteria are met.
3. At least 1 each of the following general and respiratory symptoms associated with influenza is present with a severity of moderate or greater:
i. General symptoms (headache, feverishness or chills, muscle or joint pain, or fatigue) ii. Respiratory symptoms (cough, sore throat, or nasal congestion)
The time interval between the onset of symptoms and the predose examinations is 48 hours or less. The onset of symptoms is defined as either:
1. Time of the first increase in body temperature (an increase of at least 1ºC from normal body temperature)
2. Time when the patient experiences at least 1 new general or respiratory symptom
If a women of childbearing potential, agrees to use a highly effective method of contraception for 3 months after the first dose of study drug
Patients will be considered at high risk* of influenza complications due to the presence of at least 1 of the following inclusion criteria:
1. Asthma or chronic lung disease (such as chronic obstructive pulmonary disease or cystic fibrosis)
2. Endocrine disorders (including diabetes mellitus)
3. Residents of long-term care facilities (eg, nursing homes)
4. Compromised immune system (including patients receiving corticosteroids not exceeding 20 mg of prednisolone or equivalent, and patients being treated for human immunodeficiency virus [HIV] infection with a CD4 count > 350 cells/mm³ within the last 6 months)
5. Neurological and neurodevelopmental disorders (including disorders of the brain, spinal cord, peripheral nerve, and muscle, eg, cerebral palsy, epilepsy [seizure disorders], stroke, muscular dystrophy, or spinal cord injury)
6. Heart disease (such as congenital heart disease, congestive heart failure, or coronary artery disease), excluding hypertension without any other heart-related symptoms
7. Adults aged ≥ 65 years
8. American Indians and Alaskan Natives
9. Blood disorders (such as sickle cell disease)
10. Metabolic disorders (such as inherited metabolic disorders and mitochondrial disorders)
11. Morbid obesity (body mass index ≥ 40 kg/m²)
12. Women who are within 2 weeks postpartum and are not breastfeeding

Exclusion criteria

Patients with severe influenza virus infection requiring inpatient treatment.
Patients with known allergy to oseltamivir (Tamiflu®).
Patients unable to swallow tablets or capsules.
Patients who have previously received baloxavir marboxil.
Patients weighing ≤ 40 kg.
Patients who have been exposed to an investigational drug within 30 days prior to the predose examinations.
Women who are pregnant, breastfeeding, or have a positive pregnancy test at the predose examinations. The following female patients who have documentation of either a or b below do not need to undergo a pregnancy test at the predose examinations:
1. Postmenopausal women (defined as cessation of regular menstrual periods for 2 years or more and confirmed by a follicle-stimulating hormone test)
2. Women who are surgically sterile by hysterectomy, bilateral oophorectomy, or tubal ligation
Patients with concurrent infections at the predose examinations requiring systemic antimicrobial therapy.
Patients with liver disease associated with hepatic impairment.
Patients with cancer within the last 5 years (unless nonmelanoma skin cancer).
Patients with untreated HIV infection or treated HIV infection with a CD4 count below 350 cells/mm3 in the last 6 months.
Patients with immunosuppression following organ or bone marrow transplants.
Patients exceeding 20 mg of prednisolone or equivalent dose of chronic systemic corticosteroids.
Patients who have received peramivir, laninamivir, oseltamivir, zanamivir, rimantadine, umifenovir or amantadine within 30 days prior to the predose examinations.
Patients who have received an investigational monoclonal antibody for a viral disease in the last year.
Patients with known creatinine clearance ≤ 60 mL/min.
Patients who, in the opinion of the investigator, would be unlikely to comply with required study visits, self-assessments, and interventions

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

2,184 participants in 3 patient groups, including a placebo group

Baloxavir Marboxil

Experimental group

Description:

Participants received either 40 mg or 80 mg of baloxavir marboxil orally on Day 1 based on body weight of \< 80 kg or ≥ 80 kg at Screening, respectively. Participants also received placebo to oseltamivir orally twice a day (BID) on Days 1 to 5.

Treatment:

Drug: Baloxavir Marboxil

Drug: Placebo to Oseltamivir

Oseltamivir

Active Comparator group

Description:

Participants received 75 mg oseltamivir twice a day on Days 1 to 5 and placebo to baloxavir marboxil on Day 1.

Treatment:

Drug: Placebo to Baloxavir Marboxil

Drug: Oseltamivir

Placebo

Placebo Comparator group